Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 2
2012 3
2013 4
2014 9
2015 8
2016 8
2017 15
2018 39
2019 53
2020 64
2021 75
2022 61
2023 81
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Results by year

Filters applied: . Clear all
Page 1
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Marty FM, et al. N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6. N Engl J Med. 2017. PMID: 29211658 Free article. Clinical Trial.
Letermovir was administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). ...The rates of myelotoxic and nephrotoxic events were similar in the letermovir group and the placebo group. All-cause mortality at week 48 after transplant …
Letermovir was administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). ...The rates of myelotox …
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. Limaye AP, et al. JAMA. 2023 Jul 3;330(1):33-42. doi: 10.1001/jama.2023.9106. JAMA. 2023. PMID: 37279999 Free PMC article.
No participants who received letermovir vs 5 participants (1.7%) who received valganciclovir developed CMV disease through week 28. ...Quantifiable CMV DNAemia was detected in 2.1% of participants in the letermovir group vs 8.8% in the valganciclovir group by week 2 …
No participants who received letermovir vs 5 participants (1.7%) who received valganciclovir developed CMV disease through week 28. . …
Letermovir.
[No authors listed] [No authors listed] 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000008 Free Books & Documents. Review.
No information is available on the use of letermovir during breastfeeding. Because letermovir is 99% bound to plasma proteins, the amount in milk is likely to be very low. ...
No information is available on the use of letermovir during breastfeeding. Because letermovir is 99% bound to plasma proteins, …
Letermovir.
[No authors listed] [No authors listed] 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644168 Free Books & Documents. Review.
Letermovir is an antiviral agent which targets the DNA terminal transferase complex of the cytomegalovirus (CMV) and which is used to prevent CMV reactivation in immunocompromised patients. Letermovir has been associated with mild-to-moderate serum aminotransferase …
Letermovir is an antiviral agent which targets the DNA terminal transferase complex of the cytomegalovirus (CMV) and which is used to …
Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis.
Kuhn A, Puttkammer J, Madigan T, Dinnes L, Khan S, Ferdjallah A, Kohorst M. Kuhn A, et al. Transplant Cell Ther. 2023 Jan;29(1):62.e1-62.e4. doi: 10.1016/j.jtct.2022.10.005. Epub 2022 Oct 13. Transplant Cell Ther. 2023. PMID: 36244677 Free article.
Letermovir was crushed and administered via nasogastric tube in 4 of 9 patients. Two patients received letermovir for secondary CMV prophylaxis after initial treatment with ganciclovir/valganciclovir, and the remaining 7 received letermovir for primary prophy …
Letermovir was crushed and administered via nasogastric tube in 4 of 9 patients. Two patients received letermovir for secondar …
Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
Perchetti GA, Biernacki MA, Xie H, Castor J, Joncas-Schronce L, Ueda Oshima M, Kim Y, Jerome KR, Sandmaier BM, Martin PJ, Boeckh M, Greninger AL, Zamora D. Perchetti GA, et al. Bone Marrow Transplant. 2023 Apr;58(4):430-436. doi: 10.1038/s41409-023-01920-w. Epub 2023 Jan 24. Bone Marrow Transplant. 2023. PMID: 36693927
Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who received letermovir prophylaxis from 2018 to 2020 at our center were evaluated for …
Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after allogeneic hematopoietic cell transplant …
Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Richert-Przygonska M, Jaremek K, Debski R, Konieczek J, Lecka M, Dziedzic M, Bogiel T, Styczynski J, Czyzewski K. Richert-Przygonska M, et al. Anticancer Res. 2022 Jul;42(7):3607-3612. doi: 10.21873/anticanres.15848. Anticancer Res. 2022. PMID: 35790275
Of the 13 patients of the study group, three died; however, deaths were not attributable to CMV infection. We did not observe any toxicities related to letermovir. CONCLUSION: Our data support letermovir prophylaxis efficacy and safety in pediatric patients after al …
Of the 13 patients of the study group, three died; however, deaths were not attributable to CMV infection. We did not observe any toxicities …
Letermovir for cytomegalovirus prophylaxis.
[No authors listed] [No authors listed] Aust Prescr. 2019 Jun;42(3):107. doi: 10.18773/austprescr.2019.032. Epub 2019 Apr 24. Aust Prescr. 2019. PMID: 31363312 Free PMC article. Review. No abstract available.
Letermovir: First Global Approval.
Kim ES. Kim ES. Drugs. 2018 Jan;78(1):147-152. doi: 10.1007/s40265-017-0860-8. Drugs. 2018. PMID: 29288370 Review.
Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the Eur …
Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipie …
Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients.
Saullo JL, Miller RA. Saullo JL, et al. Annu Rev Med. 2023 Jan 27;74:89-105. doi: 10.1146/annurev-med-042921-124739. Epub 2022 Nov 4. Annu Rev Med. 2023. PMID: 36332639 Free article. Review.
CMV prevention is paramount; however, selecting the best preventive strategy depends on many factors including donor-recipient CMV serostatus, transplant-specific risks, antiviral toxicities and cost. Novel CMV therapeutics such as letermovir (LTV) are desperately needed t …
CMV prevention is paramount; however, selecting the best preventive strategy depends on many factors including donor-recipient CMV serostatu …
411 results

Searches related to "letermovir"